Sacituzumab Govitecan in patients with breast cancer brain metastases and recurrent glioblastoma: a phase 0 window-of-opportunity trial

Abstract Sacituzumab Govitecan (SG) is an antibody-drug conjugate that has demonstrated efficacy in patients with TROP-2 expressing epithelial cancers. In a xenograft model of intracranial breast cancer, SG inhibited tumor growth and increased mouse survival. We conducted a prospective window-of-opp...

Full description

Bibliographic Details

Published in:	Nature Communications
Main Authors:	Henriette U. Balinda, William J. Kelly, Virginia G. Kaklamani, Kate I. Lathrop, Marcela Mazo Canola, Pegah Ghamasaee, Gangadhara R. Sareddy, Joel Michalek, Andrea R. Gilbert, Prathibha Surapaneni, Stefano Tiziani, Renu Pandey, Jennifer Chiou, Alessia Lodi, John R. Floyd, Andrew J. Brenner
Format:	Article
Language:	English
Published:	Nature Portfolio 2024-08-01
Online Access:	https://doi.org/10.1038/s41467-024-50558-9